Interim Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Operating expenses
General and administrative	$ 2,915,158	$ 2,233,745	$ 5,982,109	$ 3,704,401
Research and development	8,604,589	6,720,841	17,261,028	14,646,360
Total operating expenses	(11,519,747)	(8,954,586)	(23,243,137)	(18,350,761)
Other income (expenses)
Grant income		10,820		10,820
Research and development incentive income	835,513	960,879	1,646,243	2,230,195
Interest income, net	7,578	9,216	12,488	7,657
Foreign exchange gain (loss), net	268,645	(154,563)	324,008	178,071
Total other income, net	1,111,736	826,352	1,982,739	2,426,743
Net loss before provision for income taxes	(10,408,011)	(8,128,234)	(21,260,398)	(15,924,018)
Income tax expense, current	(29,800)	(26,988)	(59,780)	(86,269)
Net loss and comprehensive loss	$ (10,437,811)	$ (8,155,222)	$ (21,320,178)	$ (16,010,287)
Net Loss per share
Basic and diluted	$ (0.14)	$ (0.12)	$ (0.28)	$ (0.24)
Weighted average number of shares outstanding
Basic and diluted	76,248,603	68,594,867	76,121,792	66,421,380